Israeli startup RedC Biotech is pioneering large-scale production of universal red blood cells derived from stem cells to alleviate global blood shortages. Utilizing bioreactors capable of generating hundreds of transfusion-ready units, the approach aims to eliminate dependency on donors and provide cost-effective, safe blood supplies worldwide. The technology is advancing toward preclinical and clinical testing, promising to reduce mortality from blood loss and improve transfusion accessibility in emergencies and regions with inadequate donation systems.